Creative Medical Technology Holdings Inc (CELZ) last traded at $1.0400, a gain of +0.5281 (+103.16%). More than 137M shares exchanged hands compared to an average daily volume of mere 186K shares.
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotech firm striving to transform healthcare through the creation of cutting-edge regenerative therapeutics, declared today that it has obtained the go-ahead from the Institutional Review Board (IRB) to commence its Clinical Trial for the cure of Type 1 Diabetes utilizing its CELZ-201 cell therapy. The company’s Investigational New Drug (IND) application was previously approved by the U.S. Food and Drug Administration (FDA) within a record-breaking 30 days from submission.
Type 1 diabetes is a chronic disease in which the pancreas produces little or no insulin, a hormone that regulates blood sugar levels. The market for Type 1 diabetes treatments is growing due to the increasing prevalence of the disease and the development of new therapies. According to recent market research, the global Type 1 diabetes market was valued at approximately USD 16 billion in 2020 and is expected to grow at a significant rate over the next decade.
New and innovative therapies, such as cell-based therapies and artificial pancreas systems, are being developed and are expected to drive the growth of the market. In addition, the increasing awareness of Type 1 diabetes and the availability of financial support from government and private organizations are also expected to contribute to the growth of the market.
However, the high cost of treatment and limited reimbursement options in some regions may act as a hindrance to the growth of the market. Despite these challenges, the demand for effective and innovative treatments for Type 1 diabetes continues to increase, and the market is expected to grow in the coming years.
